# CJC-1295 Ipamorelin Benefits: What the Research Shows

> CJC-1295 ipamorelin benefits in preclinical and human studies: GH and IGF-1 elevation, bone mineral content, body composition, sleep architecture, and GI motility outcomes, fully cited.

## GH and IGF-1 Elevation: The Primary Axis Endpoint

CJC-1295 at 60–90 µg/kg subcutaneous elevated mean GH by 46% and mean IGF-1 by 45% at one week post-dose in healthy men, with basal GH elevated 7.5-fold and pulsatile secretion preserved.[1] Proteomic analysis confirmed downstream IGF-1-axis activation: immunoglobulin-albumin fragment levels correlated linearly with IGF-1 elevation.[6]

For GH secretagogues more broadly, MK-677 (25 mg/day, 12 months, n=65) increased fat-free mass +1.1 kg and total body weight +2.7 kg versus placebo.[17] Direct CJC-1295/ipamorelin combination data on body composition in human subjects have not been published.

## Body Composition Outcomes

In GHRH-knockout mice, once-daily CJC-1295 at 2 µg/day normalized body weight, length, lean mass, and subcutaneous fat mass.[5] Ipamorelin at 100 µg/kg three times daily SC increased maximum tetanic muscle tension significantly in rats counteracting glucocorticoid-induced muscle loss.[8] In GH-intact mice, ipamorelin increased relative body fat via GH-independent mechanisms.[19]

## Bone Mineral Content and Longitudinal Growth

Ipamorelin dose-dependently increased longitudinal bone growth rate in adult female rats from 42 µm/day to 52 µm/day over 15 days (p<0.0001).[4] Ipamorelin and GHRP-6 at 0.5 mg/kg/day for 12 weeks increased bone mineral content in adult female rats via expanded bone dimensions.[9] Ipamorelin at 100 µg/kg three times daily produced a 4-fold increase in periosteal bone formation rate in rats experiencing glucocorticoid-induced bone loss.[8]

## Sleep Architecture and Nocturnal GH Secretion

Ghrelin — the endogenous ligand at the same receptor ipamorelin binds (GHS-R1a) — administered as intravenous boluses (4 × 50 µg hourly) to seven human subjects enhanced slow-wave sleep and delta-wave activity while reducing REM sleep in the first half of the night; GH and prolactin rose substantially.[12]

## Gastrointestinal Motility

Ipamorelin dose-dependently restored gastrointestinal function in a rat model of postoperative ileus at IV doses of 0.01–1 mg/kg four times daily for 2 days, increasing cumulative fecal output, food intake, and body weight gain.[10] This GI-motility endpoint reflects GHS-R1a agonism in the enteric nervous system, distinct from the pituitary GH-axis mechanism.

## Evidence for Efficacy in Controlled Studies

- CJC-1295 Phase I/II-context trials demonstrated statistically significant increases in mean GH and IGF-1 versus baseline.[1]
- GHS synergy greater-than-additive GH release from GHRH + GHS combination confirmed across five species.[13]
- Downstream bone, body composition, GI motility, and sleep-architecture outcomes measured in rodent models.
- Combination CJC-1295/ipamorelin human efficacy data remain limited to the preclinical and pharmacokinetic record.

## Timeline of Observed Outcomes

CJC-1295 Phase II trials: IGF-1 elevation within 2 weeks; sustained for up to 28 days post-dose with DAC form.[1] Body composition and bone endpoints in animal studies: measurable changes at 4–8 weeks.[4][8][9]

## References

[1] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Johansen PB, et al. Growth Horm IGF Res. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/
[5] Alba M, et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[6] Sackmann-Sala L, et al. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[8] Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266-272. https://pubmed.ncbi.nlm.nih.gov/11735244/
[9] Svensson J, et al. J Endocrinol. 2000;165(3):569-577. https://pubmed.ncbi.nlm.nih.gov/10828840/
[10] Venkova K, et al. J Pharmacol Exp Ther. 2009;329(3):1110-1116. https://pubmed.ncbi.nlm.nih.gov/19289567/
[12] Weikel JC, et al. Am J Physiol Endocrinol Metab. 2003;284(2):E407-E415. https://pubmed.ncbi.nlm.nih.gov/12388174/
[13] Farhy LS, Veldhuis JD. Am J Physiol Regul Integr Comp Physiol. 2005;288(5):R1649-R1663. https://pubmed.ncbi.nlm.nih.gov/15718392/
[17] Smith RG, Thorner MO. J Gerontol A Biol Sci Med Sci. 2023;78(6):975-983. https://pmc.ncbi.nlm.nih.gov/articles/PMC10272984/
[19] Lall S, et al. Biochem Biophys Res Commun. 2001;280(1):132-138. https://pubmed.ncbi.nlm.nih.gov/11162489/

---

Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.